Overall, these findings support the idea that ACA administered in combination with anti-PD-1 promotes anti-tumor immunity in a manner sufficient to impede primary tumor growth in a subset of mice, using a renal cancer model that is resistant to anti-PD-1 monotherapy. This evidence concerns the gene PDCD1 and neoplasm.